Home / Intelligence / Briefs / Global Dossiers in the Joint Clinical Assessment Era: Impacts and Implications
Joint clinical assessment (JCA) is a European Union (EU) initiative intended to improve patient access to health technologies in Europe through a harmonized clinical health technology assessment (HTA) process. From January 2025, all new oncology medicines and advanced therapy medicinal products will go through the JCA process, followed by all orphan medicinal products from 2028 and all new medicines from 2030.
The JCA process will run parallel to European Medicines Agency (EMA) regulatory evaluation and will involve submission of a dossier detailing disease information, product information and clinical data, but will not include economic data, which will be assessed later, at national level.
As JCA comes into effect, manufacturers will need to carefully consider their processes for development of global value/reimbursement dossiers to ensure that they continue to meet the needs of their affiliates in Europe and beyond.
Complete the form below to access the full advisory brief
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
Related Intelligence
Webinars
Most-Favored Nation Pricing Policy: Why One Size Doesn’t Fit All
September 25, 2025 | 1:00 – 2:00 PM ET
As U.S. leaders promote a drug pricing vision based on Most-Favored Nation (MFN) principles, ensuring that U.S. consumers have access to the best available prices among advanced nations, pharmaceutical companies are facing increased uncertainty and are evaluating strategic options. This session will bring together Trinity experts to discuss how this initiative could realistically lead to […]
Sign Up Now
Blog
A Shrinking Safety Net: OBBBA’s Ripple Effects on the Pharma Industry
President Trump signed the “One Big Beautiful Bill Act” (OBBBA) into law on July 4, 2025. The OBBBA is projected to reduce federal health spending by an estimated $900 billion[1] over the next decade. Central to the legislation is the estimated loss of insurance coverage for 16 million people[2], fundamentally reshaping access to care for […]
Read More
Webinars
Part D in Peril: The Inconvenient Math of IRA Part D Redesign
Available On Demand
Medicare Part D is undergoing its most significant transformation in decades largely driven by the IRA. What does this mean for pharmaceutical manufacturers? Join us for an engaging discussion with Max Hunt, Partner at Trinity, and special guest Dan Simenc, clinical and actuarial expert at Milliman, as they provide perspectives on recent developments and future expectations for Medicare Part D and Medicare Advantage.
Watch Now